Navigation Links
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Date:7/19/2009

care, versus placebo plus standard of care, in serologically active (i.e., autoantibody-positive) patients with SLE. This is the largest clinical trial program ever conducted in lupus patients. BLISS-52 randomized and treated 865 patients at 90 clinical sites in 13 countries, primarily in Asia, South America and Eastern Europe. BLISS-76 enrolled and randomized 826 patients at 133 clinical sites in 19 countries, primarily in North America and Europe. The design of the two trials is similar, but the duration of therapy in the two studies is different - 52 weeks for BLISS-52 and 76 weeks for BLISS-76. The data from BLISS-76 will be analyzed after 52 weeks in support of a potential Biologics License Application in the United States and Marketing Authorization Application in Europe and other regions. HGS designed the Phase 3 program for belimumab in collaboration with GSK and leading international SLE experts, and the program is being conducted under a Special Protocol Assessment agreement with FDA.

The primary efficacy endpoint of BLISS-52 and BLISS-76 is the patient response rate at Week 52, as defined by: (1) a reduction from baseline of at least 4 points on the SELENA SLEDAI disease activity scale (which indicates a clinically important reduction in SLE disease activity); (2) no worsening of disease as measured by the Physician's Global Assessment (worsening defined as an increase of 0.30 points or more from baseline); and (3) no new BILAG A organ domain score (which indicates a severe flare of lupus disease activity) and no more than one new BILAG B organ domain score (which would indicate a moderate flare of disease activity). Analysis for the primary endpoint is based on intention-to-treat (ITT) and adjusted for baseline stratification factors, including SELENA SLEDAI score, proteinuria and race.

In each of the two Phase 3 trials, patients were randomized to one of three treatment groups: 10 mg/kg belimumab (BLISS-52
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Novastem, a leader in ... patient in its study for ischemic stroke at ... Association, ischemic strokes account for 87 percent of ... patients in the study, entitled "Internal Research Protocol ... Mesenchymal Stem Cells and Intrathecal Administration of Neural ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... FARMINGDALE, N.Y., Sept. 29 Misonix, Inc. (Nasdaq: ... device technology, which in Europe is used for the ... conditions, today announced plans to release fourth quarter and ... Thursday afternoon, October 1, 2009. Michael A. McManus, ...
... Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused ... of a Phase 2b trial for Empatic(TM) on Wednesday, September ... be followed by a live webcast and conference call at ... call and webcast to discuss the results of this clinical ...
Cached Medicine Technology:Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern 2
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... current state of the global Sterilizers industry with a ... statistics on the market status of the Sterilizers manufacturers ... for companies and individuals interested in the industry. This ... its definition, applications and manufacturing technology. In this part, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Product liability lawsuits filed in the ... http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal court, ... in the U.S. District Court, Northern District of Ohio ... conference on January 7, 2015, at the Paul G. ... Palm Beach, Florida. The Conference is scheduled to begin ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... , , Medtronic Featured as Official ... The American Association of Heart Failure Nurses (AAHFN) is ... February 8-14 .   , The purpose of Heart Failure Awareness ... common and debilitating condition.  AAHFN will achieve this goal through the ...
... but effective treatment, experts say , FRIDAY, Feb. 5 ... can be killed by a type of bacteria that ... maggots to disinfect wounds (maggot debridement therapy) is standard ... dead tissue and ingest bacteria that are killed in ...
... responsible for ,pending epidemic, researchers say , FRIDAY, Feb. ... patients but can cause work-related injuries in surgeons, suggests ... Medicine researchers found that 87 percent of laparoscopic surgeons ... physical symptoms or discomfort. , "We face a pending ...
... NEW YORK , Feb. 5 Hospital for ... today announced its support of the Arthritis Foundation and Ad ... raise awareness of osteoarthritis, increase public health education and support ... our extensive clinical and research resources on raising awareness of ...
... , , BEIJING, CHINA , Feb. 5 ... attention to a certain previously released news announcements namely January 7 ... January 12,2010 , and January 22, 2010 . , These ... these events are now starting to crystallize and are beginning to transform ...
... more likely to misuse prescribed drugs, suffer flareups ... patients who use herbal remedies experience increased symptoms and ... Researchers followed 326 asthma patients for 33 months. Of ... and used prescribed inhaled corticosteroids (ICS) less often than ...
Cached Medicine News:Health News:AAHFN Promotes Heart Failure Awareness Week Through Webinar 2Health News:Wound-Healing Maggots Succumb to Deadly Bacteria 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 3Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Herbals Not the Answer for Asthma, Study Shows 2
High temp cauteries, fine tip micro....
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
6 mm, 45 degree upwards, detachable....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
Medicine Products: